Effect of Sitagliptin on Endothelial Progenitor Cells

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Endothelial progenitor cells (EPCs) are involved in cardiovascular homeostasis, through angiogenesis and endothelial healing. Diabetic patients have a high risk of cardiovascular events and low levels of circulating EPCs.

Sitagliptin is an oral DPP-IV antagonist, approved for the treatment of type 2 diabetes. It increases the bioavailability of endogenous incretins, thus improving insulin and glucagon secretion. SDF-1, one of the major EPC regulators, is also a substrate of DPP-IV. This study tests the hypothesis that sitagliptin increases the levels of circulating EPCs in type 2 diabetic patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Padova
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Type 2 diabetes;

• Both genders

• Age 40-80

• fasting c-peptide >=1.0 ng/L

• Therapy with metformin or sulphonylureas

• HbA1c >7.0%

• No contraindications to sitagliptin use

Exclusion Criteria:

• Type 1 diabetes

• Age <40 or >80

• fasting c-peptide <1.0 ng/L

• Therapy with TZD

• HbA1c <=7.0%

• Acute concomitant diseases

• Immunological disorders

• Recent (within 3 months) cardiovascular events or surgery

• Pregnancy and lactation

• Inability to provide informed consent